Home/Pipeline/SER-301

SER-301

Ulcerative Colitis

Phase 1bActive

Key Facts

Indication

Ulcerative Colitis

Phase

Phase 1b

Status

Active

Company

Seres Therapeutics

About Seres Therapeutics

Seres Therapeutics is a trailblazer in the microbiome field, with a mission to transform patient lives by restoring microbiome health. Its landmark achievement is the FDA approval and commercialization of VOWST™ for recurrent C. difficile infection, validating its platform and establishing a first-mover advantage. The company's strategy involves leveraging this platform to expand into larger gastrointestinal and immunology indications, while navigating the challenges of commercial execution, pipeline development, and financial sustainability.

View full company profile

Therapeutic Areas

Infectious Disease Gastroenterology Immunology

Other Ulcerative Colitis Drugs

Drug	Company	Phase	Status
BB265	BiomeBank	Phase 1	Active
PALI-2108	Palisade Bio	Phase 2	Advancing towards initiation
ALTB-268	AltruBio	Phase IIa	Active
AIM-HI-UC	PathAI	Clinical Trials	Active
Patient Stratification in Ulcerative Colitis	Enable Medicine	Research	Active
Mesalazine (Lifecycle Management)	Dr. Falk Pharma	Approved/Phase 3	Active
AhR Agonist Program	Azora Therapeutics	Phase 1b	Active
R-3750	Virtici	Phase 1	Active
GPR35 Inhibitor	ThirtyFiveBio	Preclinical	Active
BT-600	Biora Therapeutics	Phase 1	Active
Asacol® (mesalazine)	Tillotts Pharma	Approved	Active
MB310	Microbiotica	Phase 1b	Active